"Besiege" 100 billion yuan of market centralized purchase of chronic disease drugs and start big price reduction

With the aging and the increasing pressure of medical insurance, more and more attention has been paid to the field of chronic disease drugs, and more and more chronic disease drugs have been included in the national and local procurement list Recently, Hebei provincial drug procurement center has taken the lead in the centralized procurement of 15 outpatient drugs for hypertension and diabetes After 25 "4 + 7" varieties, the third round of national procurement is expected to continue to include multiple chronic disease drugs According to the data of minenet, in 2018, the total sales volume of terminal hypertension and diabetes drugs in China's public medical institutions exceeded 100 billion yuan, with 28 evaluated varieties Recently, Hebei provincial drug procurement Center released the document of centralized procurement of outpatient drugs for hypertension and diabetes in urban and rural residents, which focused on the procurement of 15 outpatient drugs for hypertension and diabetes in urban and rural residents (referred to as "two diseases"), including 9 varieties of hypertension and 6 varieties of diabetes, as well as the Chinese patent medicine Xiaoke pill At the same time, 35 generic drugs purchased by the third national tire quantity also spread on the Internet Among them, metformin, acarbose and glimepiride are the drugs that coincide with the centralized purchase of 15 outpatient drugs in Hebei Province Different from the previous two rounds of national procurement rules with volume, Hebei Province promised to give all the market shares to the selected enterprises, making it clear that the application price shall not exceed the maximum purchase price limit, and drugs that fail to pass the consistency evaluation can also run for election Through consistency evaluation, drugs enjoy priority in this centralized purchase According to the consistency evaluation database of minenet, only 7 of the 15 generic varieties have passed the consistency evaluation, including 4 varieties of hypertension and 3 varieties of diabetes; 3 drugs with 3 or more evaluated enterprises, including captopril tablets, metformin hydrochloride tablets and glimepiride tablets; only 2 drugs with exclusive evaluation, respectively, are the salt of Asian Epson Pharmaceutical Co., Ltd Propranolol acid tablets, Changzhou pharmaceutical hydrochlorothiazide tablets Only Huadong pharmaceutical and LVYE pharmaceutical have been appraised by acarbose enterprises The varieties appraised by Ouyi are captopril and metformin, while those appraised by Xinhua Pharmaceutical are captopril and glimepiride In terms of the maximum price limit, the price limit of hydrochlorothiazide (10mg) is 0.0149 yuan / tablet, captopril (12.5mg) and nifedipine (5mg) is 0.0176 yuan / tablet, the price limit of main products of several hypertension varieties is 0.03 yuan / tablet; the price limit of diabetes varieties is 0.03 yuan / tablet, and the price limit of glibenclamide (2.5mg) is 1.36 yuan / tablet In terms of purchase volume, the highest purchase volume of high blood pressure varieties is captopril 40 million tablets, and the highest purchase volume of diabetes varieties is metformin 500 million tablets, and the two varieties are respectively 3 and 11 enterprises through the consistency evaluation A fierce price war is inevitable Centralized purchase and over evaluation of "two diseases" drugs in Hebei Province At the beginning of October this year, the State Medical Insurance Bureau and other four departments jointly issued the guiding opinions on improving the drug use guarantee mechanism of urban and rural residents' outpatient service for hypertension and diabetes, which included the urban and rural medical insurance for hypertension and diabetes in the reimbursement of medical insurance, with the reimbursement ratio no less than 50%, improving the long-term prescription system for outpatient drug use, ensuring the supply and use of drugs Greatly reduce the burden of hypertension and diabetes Recently, in response to the call of the state, many provinces have successively issued comprehensive drug use policies for hypertension and diabetes clinics According to incomplete statistics, there are already Shandong, Sichuan, Shaanxi, Jiangxi, Jiangsu, Zhejiang, Anhui, Fujian, Guangxi, Guizhou, Hebei, Ningxia, Liaoning, Gansu, Shanxi, Yunnan, Chongqing 25 provinces and cities printed and distributed provincial-level policy documents on outpatient medication of hypertension and diabetes With the aging and the change of diet, the number of patients with "two diseases" is increasing It is estimated that there are more than 300 million high blood pressure and diabetes patients in the urban and rural residents of China According to the report on cardiovascular disease in China in 2018, the number of hypertension patients in China is as high as 270 million, with a prevalence rate of 23.2%; according to the report released by the International Diabetes League in 2017, the number of diabetes patients in China is 114 million At the same time, the drug market of "two diseases" is also growing According to the data of minenet, in 2018, the sales volume of terminal antihypertensive drugs in public medical institutions in China was 55.069 billion yuan, up 12.91% year on year; in 2018, the sales volume of terminal diabetes drugs in public medical institutions in China was 512.228 billion yuan, up 12.79% year on year Sales of terminal antihypertensive drugs in public medical institutions in China (100 million yuan) Sales of terminal diabetes drugs in public medical institutions in China (10000 yuan) Consistency evaluation of diabetes drug use passing or deemed passing According to the consistency evaluation database of minenet, up to now, there are 10 varieties of diabetes drugs that have passed or deemed to pass the consistency evaluation The most popular varieties are metformin hydrochloride tablets, metformin hydrochloride sustained-release tablets and glimepiride tablets There are 11, 11 and 6 enterprises that have been evaluated respectively Among them, metformin hydrochloride tablets and metformin hydrochloride sustained-release tablets, glimepiride tablets, Acarbose Tablets and acarbose capsules are the third batch of products purchased by China Netflix The evaluated enterprises include Ouyi, Yangzi River, Huadong pharmaceutical, LVYE pharmaceutical, etc Pass or deemed pass consistency evaluation of antihypertensive drugs Different from diabetes drugs, the market competition of antihypertensive drugs is particularly fierce According to the data of minenet, up to now, 18 varieties of antihypertensive drugs have passed or deemed to pass the consistency evaluation Among them, the varieties to be included in the third round of belt quantity procurement include olmesartan ester tablets, candesartan ester tablets, bisoprolol fumarate tablets, indapamide tablets, and alisentan tablets There are 8 varieties of three evaluated enterprises, namely olmesartan ester tablets, enalapril maleate tablets, captopril tablets, candesartan ester tablets, irbesartan hydrochlorothiazide tablets, irbesartan tablets, indapamide tablets and amlodipine besylate tablets It is worth noting that among the 18 varieties of antihypertensive drugs that have been evaluated, Huahai's products occupy 6 seats, which may help Huahai to stand out in the field of antihypertensive drugs In addition, Zhengda Tianqing has 3 varieties that have been evaluated, and xinlitai, dongyangguang pharmaceutical, Shiyao, Yangzi River and other enterprises have 2 varieties that have been evaluated Aging is the stage and trend of social and economic development The continuous growth of medical expenses brought by aging also makes the pressure of medical insurance more and more The state and local government will promote the substitution of generic drugs for high price original research, let patients use high quality and low price products, accelerate the transformation of domestic mainstream pharmaceutical enterprises to innovative drug research and development, and reduce the dependence on imported new drugs.